<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82654">
  <stage>Registered</stage>
  <submitdate>5/05/2008</submitdate>
  <approvaldate>13/05/2008</approvaldate>
  <actrnumber>ACTRN12608000244303</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of Safety and Efficacy of the Flexstent Peripheral Stent System in a First in Man Study</studytitle>
    <scientifictitle>Evaluation of Safety and Efficacy of the Flexstent Peripheral Stent System in a First in Man Study in patients with superficial femoral artery diseae.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Superficial femoral artery disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single Flexstent peripheral stent system is implanted in the diseased vessel of the superficial femoral artery using the participating hospital standard procedures.
The stents are intended to remain in the diseased vessel.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy as measured by in-stent binary restenosis using ultrasound</outcome>
      <timepoint>1, 3, 6, 9, and 12 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety as measured by adverse events</outcome>
      <timepoint>1, 3, 6, 9, and 12 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rutherford measurement (scale representing severity of disease)</outcome>
      <timepoint>Pre-treatment, following treatment, 1, 6, and 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ankle brachial index</outcome>
      <timepoint>Pre-treatment, after treatment, 1, 6, and 12 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Standard treadmill test</outcome>
      <timepoint>Pre-treatment and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Walking impairment questionnaire</outcome>
      <timepoint>Pre-treatment, 1, 6, and 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Primary, primary assisted, and secondary patency.</outcome>
      <timepoint>1, 6, and 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Subjects, male or female, must be between the ages of 35 to 80 years inclusive at the time of consent. A female of childbearing potential may be enrolled, provided she has a negative pregnancy test at Screening.
2.	Subjects must give written informed consent prior to participation in the study and must understand the purpose of this study and be willing to adhere to the study procedures described in this protocol. 
3.	Rutherford Classification Category 2-4
4.	Single de novo lesion in the superficial femoral artery
5.	Disease segment length =100mm
6.	&gt;50% diameter stenosis and occlusion
7.	Patent ipsilateral iliac artery
8.	Patent ipsilateral popliteal artery and at least 1 patent tibial artery in continuity to ankle
9.	Target reference vessel diameter 3.5-5.5 mm</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Target lesion previously treated with a stent or surgery
2.	Rutherford Classification Category 0,1,5 or 6
3.	Inability to tolerate antithrombotic or antiplatelet therapies
4.	Pregnancy 
5.	Other comorbidity risks which in the opinion of the investigator limit longevity or likelihood of complying with protocol follow up.
6.	Serum creatinine &gt;180 mmol/l
7.	Myocardial infarction or stroke within 90 days of enrollment
8.	Hypercoagulable state
9.	Uncontrollable hypertension</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/05/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Flexible Stenting Solutions Inc</primarysponsorname>
    <primarysponsoraddress>23 Christopher Way, Suite 103
Eatontown, NJ 07724</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Flexible Stenting Solutions, Inc</fundingname>
      <fundingaddress>23 Christopher Way, Suite 103
Eatontown, NJ 07724</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>SJM Associates Limited</sponsorname>
      <sponsoraddress>Kuku Road
RD 14
Ashhurst</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Committee</ethicname>
      <ethicaddress>Auckland</ethicaddress>
      <ethicapprovaldate>17/04/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janet Burpee</name>
      <address>Flexible Stenting Solutions Inc.
23 Christopher Way, Suite 103
Eatontown, NJ 07724</address>
      <phone>+1 732 578-0060</phone>
      <fax />
      <email>jburpee@burpeetech.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Stuart McLachlan</name>
      <address>Kuku Road
RD 14
Ashhurst</address>
      <phone>+64 6 329-4846</phone>
      <fax />
      <email>info@sjm-nz.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Stuart McLachlan</name>
      <address />
      <phone />
      <fax />
      <email>info@sjm-nz.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>